One of the main challenges is the heterogeneity of cancer. Different cancers, and even different cells within the same tumor, can have different checkpoint defects. This variability makes it difficult to develop universal treatments. Additionally, targeting these pathways can sometimes lead to resistance, necessitating combination therapies.
